Chenhao Zhang

Chenhao Zhang

Auto-generated profile, based on publicly available information

Chenhao Zhang

Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
XZXin Zhao
Xin Zhao
CZChenhao Zhang
Chenhao Zhang
YAYi An
Yi An
ZZZixuan Zhang
Zixuan Zhang
JZJiahe Zhao
Jiahe Zhao
WCWei Cao
Wei Cao
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by polyarticular, symmetric, and aggressive inflammation of the small joints in the hands and feet, resulting in dysfunction. With progress and development in medicine, treatment of RA is constantly evolving, making several drugs available for the treatment of RA. From the nonsteroidal anti-inflammatory drugs (NSAIDs) at the start of illness to glucocorticoids and then to conventional synthetic DMARDs (csDMARDs), biologic DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs), therapeutic-use drugs for RA have been keeping pace with scientific research. However, various types of drugs have additional side effects when used over the long-term. New and emerging biological and targeted agents have been widely applied in recent years; however, the side effects have not been thoroughly investigated. In this paper, we review the research progress on liver damage caused by novel biological and targeted agents available for RA treatment. The aim is to provide a reference for rational clinical administration of such drugs.

1 January 2018 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
CZChenhao Zhang
Chenhao Zhang
CHChaolian Huang
Chaolian Huang
MWMingming Wang
Mingming Wang
XKXiaolin Kong
Xiaolin Kong
GLGuannan Liu
Guannan Liu
JWJie Wang
Jie Wang
Objective. To explore the characters of traditional Chinese medicine (TCM) syndromes after percutaneous coronary intervention (PCI) and to provide syndrome study theoretical evidence for TCM differentiation treatment after PCI through retrospective study. Methods. Patients with coronary heart disease (CHD) who underwent PCI in Cardiovascular Intervention Center of Wangjing Hospital during Dec. 2012 to Dec. 2014 and met the inclusion criteria were enrolled. Retrospective study was then conducted based on patients’ clinical document and angiography data to explore the distribution pattern of TCM syndromes. Results. 801 patients were recruited in the study. TCM syndromes in descending order of their incidence were Qi deficiency and blood stasis syndrome, heart blood stasis syndrome, Qi and Yin deficiency syndrome, phlegm and blood stasis syndrome, Qi stagnation and blood stasis syndrome, Yang asthenia syndrome, heart and kidney yin deficiency syndrome to cold congeal, and blood stasis syndrome in a more to less order. Qi deficiency and blood stasis syndrome was in the most (occurring in 298 patients, 37.20%); Qi and Yin deficiency syndrome occurred in 163 patients (20.35%); heart blood stasis syndrome was shown in 126 patients (15.73%); phlegm and blood stasis syndrome was shown in 95 patients (11.86%). Conclusion. Qi deficiency and blood stasis syndrome was closely associated with post‐PCI bleeding, implying that this syndrome might serve as a powerful predictor of GI bleeding as well as a potential supplement to the current predicting and scoring system of bleeding such as CRUSADE.

1 January 2018 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
CZChenhao Zhang
Chenhao Zhang
CHChaolian Huang
Chaolian Huang
XKXiaolin Kong
Xiaolin Kong
GLGuannan Liu
Guannan Liu
NLNing Li
Ning Li
JWJie Wang
Jie Wang
Objective. To evaluate the clinical efficacy of traditional Chinese medicine (TCM) supplementing Qi and hemostasis formula on gastrointestinal (GI) bleeding after percutaneous coronary intervention (PCI) and thus find out the optimal therapeutic regimen to reduce incidence of GI bleeding without increase of major adverse cardiovascular events (MACEs). Methods. In the randomized, double‐blinded, controlled trial, 117 participants who underwent PCI were enrolled and evenly distributed into treatment arm (59) and control arm (58). Numerous end points were assessed including the primary endpoint of GI bleeding and MACEs and secondary endpoint of thromboelastogram (TEG) (mainly MAadp, inhibition of ADP, and inhibition of AA) and TCM syndrome score during the follow‐up phase of 90 days. Results. Incidence of bleeding including GI bleeding and MACE did not differ significantly between two arms (28.82% in treatment arm versus 24.44% in control). However, on both days 30 and 90, TCM treatment remarkably reduced the TCM syndrome total score with notable alteration (P<0.05) except for some parameters such as pulse manifestation. When it came to TEG, however, MAADP increased significantly on day 30 in control arm, accompanied by a notable descending in inhibition rate of ADP pathway (both P<0.01). Conclusion. (1) Supplementing Qi and hemostasis formula is equal to Pantoprazole Sodium Enteric‐Coated Capsule in hemostasis and gastric mucosal protection; (2) supplementing Qi and hemostasis formula is superior to Pantoprazole Sodium Enteric‐Coated Capsule in improving TCM syndrome manifestation possibly through the multitarget mechanism; (3) interference on clopidogrel of supplementing Qi and hemostasis formula might be much less than Pantoprazole Sodium Enteric‐Coated Capsule due to the potential CYP450‐independent mechanism. This trial is registered with ChiCTR1800014485.